|
Industry report
HighTech Business Decisions has just published its 6th comprehensive industry report on biopharmaceutical contract manufacturing: “Biopharmaceutical Contract Manufacturing 2005: Improved Processes and New Capacity for Pipeline to Commercial Production.”
- Learn how improved processes, higher yields, capacity configurations, and increased efficiencies are changing the competitive landscape for biopharmaceutical contract manufacturers.
- Find out about opportunities in the production of biologics: recombinant proteins, monoclonal antibodies, antibody drug conjugates, antibody fragments, plasmid DNA, gene therapy, vaccines, novel proteins
- Understand market size, growth, and how contractors and clients are forging successful partnerships.
The Report
This 850-page report provides the latest information on worldwide outsourcing of biopharmaceutical production and the challenges ahead so readers can make successful strategic decisions.
Volume I: Key Chapters
- Chapter 3: Market Overview Analysis of the biopharmaceutical contract manufacturing market size worldwide and expected growth, technology and capacity issues, segmentation by technology and service, user requirements, needed services, new trends, product types, and the changing competitive environment.
- Chapter 4: Client Requirements Based on in-depth interviews with 51 biomanufacturing and outsourcing directors at pharmaceutical and biotechnology companies worldwide, the report includes a full analysis of product types and portfolio mix, pre-clinical products and outsourcing trends, process development outsourcing, capacity needed currently and in three to five years, tank sizes, biomanufacturing technologies, impact of manufacturing efficiencies including expression systems and disposables, outsourcing decisions and strategies, benefits and drawbacks of outsourcing, products and services likely to be outsourced, contractor selection and evaluation tools, prices paid and outsourcing budgets, future plans, low-cost regions, biogenerics, and observations on the future of the contract biomanufacturing market.
-
Chapter 5: Contractors In-depth interviews with 33 contractors provide information on manufacturing improvements and efficiencies, capacity, revenues, profit margins, growth, customer base, products manufactured, tank sizes, technologies, organizational changes, sales and marketing practices, biogenerics, and observations on industry trends.
Volume II
- Appendix A: Write-ups of in-depth interviews with 51 biomanufacturing directors at pharmaceutical and biotechnology companies worldwide, edited and coded for confidentiality
- Appendix B: Directory of biopharmaceutical contract manufacturers, including detailed profiles of 96 CMOs: contract biomanufacturers, transgenics suppliers, biomanufacturing fill and finish providers, and biomanufacturing support suppliers
- Appendix C: Survey Questionnaire for pharmaceutical and biotechnology company respondents
- Appendix D: Survey Questionnaire for biopharmaceutical contract manufacturers
Order form at http://www.hightechdecisions.com/of_midc.html
About Us
Information about the authors' : Sandra Fox, MBA, Richard Khoury Ph.D., Lynne Sopchak Ph.D., and Helen Wang, Ph.D. can be found on the HighTechDecisions website at http://www.hightechdecisions.com/about.html
|
|
